Arena Pharmaceuticals (ARNA) inked a deal with United Therapeutics (UTHR) to sell and develop its Phase 3 investigational drug candidate ralinepag worldwide. Under the agreement terms, Arena Pharma will receive $800 million from United Therapeutics plus $400 million as additional milestone payments based on achieving certain regulatory events. Shares of Arena jumped about 25% during … Continue reading Arena Pharmaceuticals soars on the $1.2 billion deal with United Therapeutics